1 Response to treatment |
14 |
574 |
Risk Ratio (M‐H, Random, 95% CI) |
1.11 [0.86, 1.44] |
2 Mental state: 1a. General ‐ overall symptoms ‐ average endpoint score/change (BPRS, high = poor) |
4 |
133 |
Mean Difference (IV, Random, 95% CI) |
‐0.09 [‐2.15, 1.96] |
3 Mental state: 1b. General ‐ overall symptoms ‐ average endpoint score/change (PANSS, high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
3.1 total |
1 |
41 |
Mean Difference (IV, Random, 95% CI) |
‐4.0 [‐20.69, 12.69] |
3.2 positive |
1 |
41 |
Mean Difference (IV, Random, 95% CI) |
‐1.0 [‐6.77, 4.77] |
3.3 negative |
1 |
41 |
Mean Difference (IV, Random, 95% CI) |
‐0.10 [‐5.20, 5.00] |
4 Global state: Average endpoint score/change (CGI, high = poor) |
3 |
117 |
Mean Difference (IV, Random, 95% CI) |
0.09 [‐0.31, 0.50] |
5 Relapse |
5 |
141 |
Risk Ratio (M‐H, Random, 95% CI) |
0.64 [0.26, 1.57] |
6 Leaving the study early |
11 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
6.1 due to any reason |
11 |
408 |
Risk Ratio (M‐H, Random, 95% CI) |
0.82 [0.38, 1.77] |
6.2 due to adverse effects |
11 |
408 |
Risk Ratio (M‐H, Random, 95% CI) |
0.44 [0.16, 1.20] |
6.3 due to inefficacy |
10 |
378 |
Risk Ratio (M‐H, Random, 95% CI) |
0.63 [0.31, 1.29] |
7 Adverse effects: 1. General ‐ at least one adverse effect |
5 |
158 |
Risk Ratio (M‐H, Random, 95% CI) |
1.97 [0.69, 5.66] |
8 Adverse effects: 2a. Specific ‐ movement disorders |
12 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
8.1 at least one movement disorder |
5 |
170 |
Risk Ratio (M‐H, Random, 95% CI) |
1.64 [1.22, 2.21] |
8.2 akathisia |
4 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
1.27 [0.56, 2.90] |
8.3 dyskinesia |
1 |
38 |
Risk Ratio (M‐H, Random, 95% CI) |
3.0 [0.34, 26.33] |
8.4 dystonia |
5 |
193 |
Risk Ratio (M‐H, Random, 95% CI) |
4.71 [1.95, 11.36] |
8.5 loss of associated movement |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
7.33 [0.39, 137.68] |
8.6 oculogyric crisis |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
3.14 [0.13, 74.98] |
8.7 rigor |
1 |
16 |
Risk Ratio (M‐H, Random, 95% CI) |
5.0 [0.28, 90.18] |
8.8 tremor |
2 |
127 |
Risk Ratio (M‐H, Random, 95% CI) |
2.17 [0.16, 29.13] |
8.9 use of antiparkinson medication |
6 |
165 |
Risk Ratio (M‐H, Random, 95% CI) |
2.88 [1.19, 7.00] |
9 Adverse effects: 2b. Specific ‐ movement disorders ‐ average endpoint score/change (ESRS, high = poor) |
2 |
78 |
Mean Difference (IV, Random, 95% CI) |
2.01 [1.35, 2.68] |
10 Adverse effects: 3. Others |
9 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
10.1 allergy ‐ allergic reactions |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
3.14 [0.13, 74.98] |
10.2 allergy ‐ rash |
1 |
38 |
Risk Ratio (M‐H, Random, 95% CI) |
3.0 [0.13, 69.31] |
10.3 allergy ‐ tongue alterations |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.50 [0.28, 0.90] |
10.4 anticholinergic ‐ blurring of vision |
2 |
124 |
Risk Ratio (M‐H, Random, 95% CI) |
0.78 [0.35, 1.70] |
10.5 anticholinergic ‐ constipation |
3 |
155 |
Risk Ratio (M‐H, Random, 95% CI) |
1.53 [0.21, 11.20] |
10.6 anticholinergic ‐ drooling |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
2.10 [0.20, 22.26] |
10.7 anticholinergic ‐ dry mouth |
4 |
195 |
Risk Ratio (M‐H, Random, 95% CI) |
0.85 [0.63, 1.15] |
10.8 anticholinergic ‐ micturition disturbances |
1 |
41 |
Risk Ratio (M‐H, Random, 95% CI) |
0.21 [0.01, 4.11] |
10.9 anticholinergic ‐ repercussions on sexual life |
1 |
41 |
Risk Ratio (M‐H, Random, 95% CI) |
0.21 [0.01, 4.11] |
10.10 anticholinergic ‐ sweating |
1 |
41 |
Risk Ratio (M‐H, Random, 95% CI) |
3.15 [0.36, 27.83] |
10.11 anticholinergic ‐ urinary retention |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.12 cardiovascular ‐ ankle edema |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.13 cardiovascular ‐ dizziness |
2 |
127 |
Risk Ratio (M‐H, Random, 95% CI) |
0.36 [0.21, 0.62] |
10.14 cardiovascular ‐ hypotension |
6 |
251 |
Risk Ratio (M‐H, Random, 95% CI) |
0.32 [0.10, 1.07] |
10.15 cardiovascular ‐ orthostatic symptoms |
1 |
41 |
Risk Ratio (M‐H, Random, 95% CI) |
0.35 [0.16, 0.78] |
10.16 cardiovascular ‐ palpitations |
1 |
41 |
Risk Ratio (M‐H, Random, 95% CI) |
0.30 [0.07, 1.28] |
10.17 cardiovascular ‐ syncope |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.15 [0.01, 2.81] |
10.18 central nervous system ‐ asthenia |
1 |
41 |
Risk Ratio (M‐H, Random, 95% CI) |
2.10 [0.98, 4.51] |
10.19 central nervous system ‐ confusion |
1 |
30 |
Risk Ratio (M‐H, Random, 95% CI) |
2.65 [0.12, 60.21] |
10.20 central nervous system ‐ excitement |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.21 central nervous system ‐ headache |
2 |
127 |
Risk Ratio (M‐H, Random, 95% CI) |
2.67 [0.50, 14.19] |
10.22 central nervous system ‐ nausea |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.57 [0.28, 8.94] |
10.23 central nervous system ‐ photosensitivity |
3 |
134 |
Risk Ratio (M‐H, Random, 95% CI) |
0.41 [0.05, 3.39] |
10.24 central nervous system ‐ sedation |
2 |
44 |
Risk Ratio (M‐H, Random, 95% CI) |
0.30 [0.11, 0.82] |
10.25 central nervous system ‐ sleep disturbances |
1 |
41 |
Risk Ratio (M‐H, Random, 95% CI) |
6.30 [0.83, 47.80] |
10.26 central nervous system ‐ somnolence |
5 |
224 |
Risk Ratio (M‐H, Random, 95% CI) |
0.91 [0.49, 1.72] |
10.27 hormonal ‐ amenorrhoea |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.28 metabolic ‐ weight gain |
3 |
88 |
Risk Ratio (M‐H, Random, 95% CI) |
0.22 [0.06, 0.81] |
10.29 metabolic ‐ weight loss |
2 |
68 |
Risk Ratio (M‐H, Random, 95% CI) |
0.60 [0.06, 6.06] |